Pune-based biotechnology company, Gennova Pharmaceuticals, recently acquired government funding for its mRNA-based vaccine and plans to start with human trials in October of this year.
Gennova plans to launch their vaccine by March 2021, provided their Phase I and II clinical trials are successful.
mRNA vaccines are believed to cut down the duration of vaccine development timelines. Two other such vaccines are currently undergoing trials across the world, being developed by Moderna and Pfizer BioNTech.
India is one of the largest vaccine manufacturers in the world and multiple global entities are considering it to be a nation with promising potential in terms of Covid-19 vaccines’ mass production.
Gennova started its vaccine program in collaboration with United States’ HDT Bio in January earlier this year. To begin with, they are planning to mass produce around 200 million doses next year.
Other domestic companies working on potential vaccines are Pune’s Serum Institute, Hyderabad’s Bharat Biotech (Covaxin), Ahmedabad’s Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E.